Cns Pharmaceuticals Stock Today
| CNSP Stock | USD 0.12 0.01 7.69% |
Performance0 of 100
| Odds Of DistressOver 88
|
Cns Pharmaceuticals is selling at 0.12 as of the 25th of November 2024; that is 7.69 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.11. Cns Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Cns Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of December 2023 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of November 2019 | Category Healthcare | Classification Health Care |
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company was incorporated in 2017 and is based in Houston, Texas. Cns Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 40.75 M outstanding shares of which 1.14 M shares are currently shorted by private and institutional investors with about 0.04 trading days to cover. More on Cns Pharmaceuticals
Moving together with Cns Stock
Moving against Cns Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cns Stock Highlights
| President CEO | JD Esq | |||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsCns Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cns Pharmaceuticals' financial leverage. It provides some insight into what part of Cns Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Cns Pharmaceuticals (CNSP) is traded on NASDAQ Exchange in USA. It is located in 2100 West Loop South, Houston, TX, United States, 77027 and employs 3 people. Cns Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.28 M. Cns Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 40.75 M outstanding shares of which 1.14 M shares are currently shorted by private and institutional investors with about 0.04 trading days to cover.
Cns Pharmaceuticals currently holds about 8.96 M in cash with (14.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cns Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationCns Pharmaceuticals holds a total of 40.75 Million outstanding shares. Almost 98.1 percent of Cns Pharmaceuticals outstanding shares are held by general public with 1.2 (percent) owned by insiders and only 0.7 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cns Ownership Details
Cns Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Fmr Inc | 2024-09-30 | 0.0 | |
| Vanguard Group Inc | 2024-06-30 | 0.0 | |
| Anson Funds Management Lp | 2024-09-30 | 0.0 | |
| Armistice Capital, Llc | 2024-06-30 | 0.0 | |
| Fsm Wealth Advisors, Llc | 2024-06-30 | 0.0 | |
| Virtu Financial Llc | 2024-06-30 | 0.0 | |
| Xtx Topco Ltd | 2024-06-30 | 0.0 | |
| Two Sigma Securities, Llc | 2024-06-30 | 0.0 | |
| Plante Moran Financial Advisors Lp | 2024-09-30 | 0.0 | |
| Geode Capital Management, Llc | 2024-09-30 | 203.2 K | |
| Ubs Group Ag | 2024-06-30 | 2.6 K |
Cns Pharmaceuticals Historical Income Statement
Cns Stock Against Markets
Additional Tools for Cns Stock Analysis
When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.